Back to top
more

Gilead Sciences, Inc. (GILD)

(Real Time Quote from BATS)

$65.83 USD

65.83
3,659,393

+0.62 (0.95%)

Updated Oct 22, 2019 09:41 AM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | C Growth | A Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?

During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.

GHDX AMGN GILD EXAS

Sweta Killa

What's in Store for Healthcare ETFs in Q3 Earnings?

With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.

MRK PFE ABBV BMY XLV VHT FHLC IYH GILD AMGN

Zacks Equity Research

Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?

During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.

GILD ACHN AMGN ALXN

Zacks Equity Research

Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.

MRK GILD ALXN GLPG

Zacks Equity Research

Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

PFE MRK NVS GILD

Zacks Equity Research

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $65.23, marking a -0.18% move from the previous day.

GILD

Zacks Equity Research

Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.

PFE LLY AMGN GILD

Zacks Equity Research

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GILD

Zacks Equity Research

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth

RHHBY GILD AMGN BIIB

Zacks Equity Research

The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar

The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar

CSCO BAC SAP CAT GILD

Mark Vickery

Top Stock Reports for Cisco, SAP & Gilead

Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), SAP (SAP) and Gilead Sciences (GILD).

SAP MO GILD CSCO CAT BAC

Zacks Equity Research

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $63.99, moving +1.15% from the previous trading session.

GILD

Zacks Equity Research

Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.

BLUE ZIOP GILD JAZZ

Zacks Equity Research

Why Gilead (GILD) Could Beat Earnings Estimates Again

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GILD

Zacks Equity Research

Gilead-Galapagos Report Efficacy & Safety Results on RA Drug

Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.

LLY NVO GLPG GILD

Zacks Equity Research

Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

Key highlights of the past week include label expansion of drugs, licensing deals and more.

PFE VSTM ACAD GILD IONS AKCA

Zacks Equity Research

Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan

Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.

ABBV LLY GLPG GILD

Zacks Equity Research

Novo Nordisk Focuses on Pipeline Development Amid Competition

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.

MRK NVO LLY GILD

Zacks Equity Research

Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion

Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.

NVO MRK GSK GILD

Zacks Equity Research

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $62.23, marking a +0.99% move from the previous day.

GILD

Zacks Equity Research

AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug

AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.

MRK ABBV NVS GILD

Zacks Equity Research

Enanta's Stock Down Despite NASH Drug Meeting Goal in Study

Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.

NVO GILD ICPT ENTA

Zacks Equity Research

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $64.20, marking a -0.56% move from the previous day.

GILD

Zacks Equity Research

Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval

Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.

RHHBY NVS NVO GILD

Zacks Equity Research

Merck's Two HIV Drugs Get FDA Approval for Expanded Use

Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.

RHHBY MRK GSK GILD